Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2017 1
2018 1
2019 1
2021 1
2022 2
2023 1
2024 3
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for R. alkali[au]
Your search for R. Aliali[au] retrieved no results
Risk prediction for clonal cytopenia: multicenter real-world evidence.
Xie Z, Komrokji R, Al Ali N, Regelson A, Geyer S, Patel A, Saygin C, Zeidan AM, Bewersdorf JP, Mendez L, Kishtagari A, Zeidner JF, Coombs CC, Madanat YF, Chung S, Badar T, Foran J, Desai P, Tsai C, Griffiths EA, Al Malki MM, Amanam I, Lai C, Deeg HJ, Ades L, Arana Yi C, Osman AEG, Dinner S, Abaza Y, Taylor J, Chandhok N, Soong D, Brunner AM, Carraway HE, Singh A, Elena C, Ferrari J, Gallì A, Pozzi S, Padron E, Patnaik MM, Malcovati L, Savona MR, Al-Kali A. Xie Z, et al. Blood. 2024 Nov 7;144(19):2033-2044. doi: 10.1182/blood.2024024756. Blood. 2024. PMID: 38996210 Free PMC article.
Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors.
Numan Y, Abdel Rahman Z, Grenet J, Boisclair S, Bewersdorf JP, Collins C, Barth D, Fraga M, Bixby DL, Zeidan AM, Yilmaz M, Desai P, Mannis G, Deutsch YE, Abaza Y, Dinner S, Frankfurt O, Litzow M, Al-Kali A, Foran JM, Sproat LZ, Jovanovic B, Daver N, Perl AE, Altman JK. Numan Y, et al. Am J Hematol. 2022 Mar 1;97(3):322-328. doi: 10.1002/ajh.26447. Epub 2022 Jan 7. Am J Hematol. 2022. PMID: 34981560 Free article. Clinical Trial.
Gilteritinib is approved for the treatment of relapsed/refractory (R/R) acute myeloid leukemia (AML) with an FLT3-mutation (FLT3(mut+) ). However, the gilteritinib phase 3 ADMIRAL study (Perl et al NEJM 2019) was conducted prior to widespread adoption of either mido …
Gilteritinib is approved for the treatment of relapsed/refractory (R/R) acute myeloid leukemia (AML) with an FLT3-mutation (FL …
TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance.
Tefferi A, Abdelmagid M, Loscocco GG, Fathima S, Begna KH, Al-Kali A, Foran J, Palmer J, Badar T, Patnaik MM, Reichard KK, He R, Zepeda Mendoza CJ, Shah M, Orazi A, Arber DA, Pardanani A, Vannucchi AM, Hiwase D, Gangat N, Guglielmelli P. Tefferi A, et al. Am J Hematol. 2025 Apr;100(4):552-560. doi: 10.1002/ajh.27609. Epub 2025 Jan 28. Am J Hematol. 2025. PMID: 39873146 Free PMC article.
Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent.
Gangat N, Elbeih A, Ghosoun N, McCullough K, Aperna F, Johnson IM, Abdelmagid M, Al-Kali A, Alkhateeb HB, Begna KH, Elliott M, Mangaonkar A, Matin A, Saliba AN, Hefazi Torghabeh M, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Badar T, Murthy H, Foran J, Palmer J, Sproat L, Khera N, Arana Yi C, Yates S, Sneider A, Dworkin E, Patel AA, Bazinet A, Senapati J, Bataller A, DiNardo C, Kadia T, Tefferi A. Gangat N, et al. Am J Hematol. 2025 Feb;100(2):260-271. doi: 10.1002/ajh.27564. Epub 2024 Dec 13. Am J Hematol. 2025. PMID: 39671248 Free PMC article.
A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndrome.
Garcia-Manero G, Gaddh M, Platzbecker U, Lindsley RC, Larson SM, Chevassut T, Fenaux P, Komrokji R, Lyons R, Al-Kali A, Jiang Y, Bothos J, Townsley DM, Zeidan AM. Garcia-Manero G, et al. Ann Hematol. 2025 Mar;104(3):1577-1585. doi: 10.1007/s00277-024-06081-4. Epub 2025 Mar 28. Ann Hematol. 2025. PMID: 40153010 Free PMC article. Clinical Trial.
A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML.
Garcia-Manero G, McCloskey J, Griffiths EA, Yee KWL, Zeidan AM, Al-Kali A, Deeg HJ, Sabloff M, Keating MM, Zhu N, Gabrail NY, Fazal S, Maly J, Odenike O, DeZern AE, O'Connell CL, Roboz GJ, Busque L, Buckstein R, Amin H, Leber B, Shastri A, Oganesian A, Keer HN, Azab M, Savona MR. Garcia-Manero G, et al. Future Oncol. 2025 Apr;21(8):929-941. doi: 10.1080/14796694.2025.2468578. Epub 2025 Mar 6. Future Oncol. 2025. PMID: 40051275 Free PMC article.
Phase 1/1b study of azacitidine and hedgehog pathway inhibitor sonidegib in patients with myeloid neoplasms.
Tibes R, Kosiorek HE, Dueck AC, Palmer J, Sproat L, Bogenberger J, Hashmi S, Mesa R, Hogan W, Litzow MR, Al-Kali A. Tibes R, et al. Cancer. 2023 Aug 1;129(15):2321-2330. doi: 10.1002/cncr.34800. Epub 2023 Apr 11. Cancer. 2023. PMID: 37042080 Free article. Clinical Trial.
METHODS: Sonidegib (SON), an oral HHi, was tested in this phase 1/1b trial in combination with azacitidine (AZA, 75 mg/m(2) days 7) in patients with newly diagnosed and relapsed/refractory (r/r) chronic MN or acute myeloid leukemia (AML). RESULTS: Sixty-two patients …
METHODS: Sonidegib (SON), an oral HHi, was tested in this phase 1/1b trial in combination with azacitidine (AZA, 75 mg/m(2) days 7) in patie …
Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 Mutations.
Venable ER, Chen D, Chen CP, Bessonen KR, Nguyen PL, Oliveira JL, Reichard KK, Hoyer JD, Althoff SD, Roh DJ, Miller MA, Begna K, Patnaik MM, Litzow MR, Al-Kali A, Viswanatha DS, He R. Venable ER, et al. Am J Clin Pathol. 2021 Sep 8;156(4):679-690. doi: 10.1093/ajcp/aqab010. Am J Clin Pathol. 2021. PMID: 33978189 Free PMC article.
In MDS-SF3B1, Revised International Prognostic Scoring System (IPSS-R) score greater than 3 and transcription factor (TF) comutations were adverse prognostic markers by both univariate and multivariate analyses. ...However it may not provide sharp prognostication within MD …
In MDS-SF3B1, Revised International Prognostic Scoring System (IPSS-R) score greater than 3 and transcription factor (TF) comutations …
DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation.
Jawad M, Afkhami M, Ding Y, Zhang X, Li P, Young K, Xu ML, Cui W, Zhao Y, Halene S, Al-Kali A, Viswanatha D, Chen D, He R, Zheng G. Jawad M, et al. Front Oncol. 2022 Feb 28;12:849376. doi: 10.3389/fonc.2022.849376. eCollection 2022. Front Oncol. 2022. PMID: 35296003 Free PMC article.
DNMT3A mutations play a prominent role in clonal hematopoiesis and myeloid neoplasms with arginine (R)882 as a hotspot, however the clinical implications of R882 vs. non-R882 mutations in myeloid neoplasms like myelodysplastic syndrome (MDS) is unclear. ...
DNMT3A mutations play a prominent role in clonal hematopoiesis and myeloid neoplasms with arginine (R)882 as a hotspot, however the c …
14 results